Finally, the selective AVPR2 antagonist tolvaptan, which blocks cAMP production in response to AVP, presently the only drug approved for the treatment of ADPKD (21), increased YAP phosphorylation in a dose-dependent manner in MDCKII cells (Supplemental Figure 3I). Here, AVPR2 is linked to autosomal dominant polycystic kidney disease.